A recent review has connected various clinical events to redox factors and OS in cardiovascular pathophysiology, providing evidence for new pharmacological therapies such as OFAs, non-selective beta-blockers, and microRNAs (Mohd-Nor et al., 2022)
The short answer: yes, but with a few important caveats
Unlike mitochondria, peroxisomes cannot further metabolize acetylcarnitine and therefore peroxisomes are a major source of acyl groups in the form of acetate and acetylcarnitine
That third pathway, glucagon, increases energy expenditure by promoting the breakdown of stored fat, which may explain why early trial results have been striking
D o not shake
This process may help support fat burning, endurance, and reduced muscle fatigue during exercise